XORTX Therapeutics Inc.
No enriched coverage for $XRTX in the last 7 days.
No SEC Form 4 filings for $XRTX in the last 30 days.
See all $XRTX insider activity →IM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.
XORTX Therapeutics (XRTX) shares rose 12% after announcing plans to submit an Investigational New Drug application to the FDA in Q4 2026. The stock traded at $1.8997, up from $1.99, with a 52-week range of $1.59 to $7.05.
XORTX Therapeutics plans to submit an Investigational New Drug application to the FDA in Q4 2026 for its gout treatment XRx-026. The company aims to file a New Drug Application in 2027, targeting a $700M+ U.S. market. The submission follows positive clinical trial results and FDA discussions.
Recent XRTX coverage spans financial news, market movers and regulation.
Regulatory filing plan adds upside potential for the upcoming trial.
The IND filing plan signals upcoming clinical progress, likely driving further upside.
The IND filing signals progression toward an NDA, potentially unlocking significant upside if approved, given the $700M U.S. market opportunity.
Initiation of manufacturing supports the upcoming XRX-OXY-102 trial and future NDA filing, reducing supply risk.
Board leadership change may affect governance optics and committee continuity, but the release provides no operational or financial guidance changes.
AlphAI scores every news story that mentions XRTX with an AI model for sentiment and relevance, and aggregates insider trades from XORTX Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.
2 min readXORTX Therapeutics (XRTX) shares rose 12% after announcing plans to submit an Investigational New Drug application to the FDA in Q4 2026. The stock traded at $1.8997, up from $1.99, with a 52-week range of $1.59 to $7.05.
1 min readXORTX Therapeutics plans to submit an Investigational New Drug application to the FDA in Q4 2026 for its gout treatment XRx-026. The company aims to file a New Drug Application in 2027, targeting a $700M+ U.S. market. The submission follows positive clinical trial results and FDA discussions.
2 min readXORTX Therapeutics (NASDAQ: XRTX) has begun manufacturing GMP drug substance and commercial-scale tablets for its XORLO™ gout treatment. This supports the planned XRX-OXY-102 clinical study and future FDA marketing approval. The company aims to address unmet needs in gout treatment with its proprietary oxypurinol formulation.
2 min readXORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said director Anthony Giovinazzo will resign from its board for personal reasons. The company thanked him for his multi-year role as board chairman and work on key committees. XORTX also reiterated its late-stage gout and kidney disease drug development pipeline.
2 min readXORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said it appointed Depesh Narotam as an independent director effective July 27, 2026. He will sit on the Compensation, Governance and Nominating Committee. The company also outlined its late-stage pipeline for gout and kidney disease, including XRx-026, XRx-008, and XRx-101.
2 min readXORTX Therapeutics Inc. (NASDAQ: XRTX; TSXV: XRTX) said it has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company cited costs and administrative burden from maintaining a dual listing and differences in regulatory environments. It expects no shareholder action; Canadian shareholders will still trade on Nasdaq.
2 min readXORTX Therapeutics has priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share, aiming to raise US$5 million in gross proceeds. The offering is expected to close around May 15, 2026, subject to regulatory approvals. Following this announcement, XRTX's stock experienced a significant negative market reaction, declining by 23.20%.
2 min readXORTX Therapeutics Inc. filed an EFFECT Form with the SEC, which became effective on May 13, 2026. This filing, with accession number 0001104659-26-057834, is a POS AM submission indicating a post-effective amendment. The company, trading under NASDAQ: XRTX, has a market cap of $3.76 million and is involved in biotechnology.
2 min readXORTX Therapeutics (XRTX) significantly reduced its net loss to US$2.66 million in 2025 due to progress in late-stage clinical programs for gout and kidney diseases, with a New Drug Application (NDA) filing targeted within 12 months. Despite this financial improvement, the company's cash reserves dwindled, emphasizing the need for critical ongoing funding to manage regulatory and market risks. This information is derived from an AI-generated summary of their SEC 20-F Annual Report.
4 min read
